Total : %
04.02.20 10:55:33AM
Past Data
| Ticker | Date | Current phase | Disease Area | Market cap | BIOTECH CALCULATOR % PROBABILITY | Trial outcome |
|---|---|---|---|---|---|---|
| ITEK | 08/19/2017 | 3 | Opthalmology | $240M | 40.9 | fail |
| AGRX | 08/19/2017 | 3 | other | $143.73m | 47.5 | fail |
| OTIC | 08/19/2017 | 3 | Infectious disease | $489.15M | 51.85 | success |
| TENX | 08/19/2017 | 3 | Other | $65.24M | 47.5 | fail |
| ANTH | 08/19/2017 | 3 | Autoimmune | $89.3m | 34.1 | Fail |
| OPHT | 08/19/2017 | 3 | Ophthalmology | $1.3B | 52.6 | fail |
| NOVN | 08/19/2017 | 3 | Skin infections | $305m | 51.75 | fail 1/27 |
| CATB | 08/19/2017 | 2 | other | $75.1M | 31.9 | fail |
| TRVN | 08/19/2017 | 3 | other | $372M | 50.75 | success |
| AVIR | 08/19/2017 | 2 | infections disease | $48.69M | 33.55 | fail |
| AXON | 08/19/2017 | 2 | Dementia | $1.22B | 11.7 | |
| NDRM | 08/19/2017 | 2 | Neurology | $600.73m | 29.4 | Success |
| CELG | 08/19/2017 | 3 | Multiples Scerosis (Other) | 94B | 59.2 | Success |
| CDTX | 08/19/2017 | 2 | Infection | $195.08M | 33.55 | fail |
| CYCC | 08/19/2017 | 3 | Other | $22M | 47.5 | fail |
| BCRX | 08/19/2017 | 2 | -- | $406.21M | ||
| LJPC | 08/19/2017 | 3 | Cardiovascular | 332.59M | 41.95 | Success* |
| ACOR | 08/19/2017 | 3 | Neurology/Parkinson's dz | $943M | 52.05 | Success |
| PTCT | 08/19/2017 | 3 | Other | $448.54M | 50.2 | fail |
| AUPH | 08/19/2017 | 2 | Autoimmune | $196.65m | 27.5 | Success |
| KPTI | 08/19/2017 | 2 | Other | $570.81M | 31.9 | fail |
| TGTX | 08/19/2017 | 3 | Other | $292.81M | 47.5 | Success* |
| IONS | 08/19/2017 | 3 | Other | $6.10B | 59.2 | Success |
| NKTR | 08/19/2017 | 3 | Other (Opiod) | $2.37B | 59.2 | Success |
| CRBP | 08/19/2017 | 2 | Cystic Fibrosis (Other) | $462.67M | 34.6 | |
| GNMX | 2 | Other | $219.99M | 31.9 | fail | |
| LLY | 3 | Other (Breast Cancer) | $88.38B | 59.2 | Success | |
| RARE | 2 | Other (Seizure) | $3.27b | 43.6 | FAIL | |
| XENE | 2 | Other (facial acne) | 176.67M | 31.9 | fail | |
| FOMX | 3 | All indications | $338.23M | 44.5 | FAIL | |
| VRTX | 3 | Other (Cystic Fibrosis) | $22.28B | 55.7 | Success | |
| PRTK | 3 | Infections disease | $495.86M | 51.85 | Success | |
| NVCR | 3 | Oncology | $713.52M | 33.7 | Success | |
| OMED | 2 | Oncology | $327.61M | 26.35 | Fail | |
| RARE | 3 | Other | $2.50B | 59.2 | Success | |
| NTRP | 2 | Alzheimer's | $147.43M | 9.9 | Fail | |
| AEZS | 3 | Other | $49.93M | 48.4 | Fail | |
| ITEK | 2 | Opthalmology | 46.55M | 33.75 | Fail | |
| ZYNE | 2 | Others | $200M | 31.9 |
